Skip to main content

Advertisement

SpringerLink
Log in

High percentage of α1-globulin in serum protein is associated with unfavorable prognosis in non-small cell lung cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The association of the percentage composition of serum protein in patients undergoing lung resections for non-small cell lung cancer (NSCLC) with overall survival and recurrence-free survival has never been investigated. Patients were selected consecutively from the database of the Bio-Bank of Shandong Provincial Hospital. We retrospectively examined the impact of preoperative percentage composition of serum protein detected by serum protein electrophoresis on survival. Furthermore, we investigated the relationships between the potential prognostic biomarkers and clinicopathological factors. A total of 390 patients were evaluated. The higher percentage of α1-globulin in serum protein was significantly associated with histology type (p < 0.001), worse tumor status (p < 0.001) and higher pathological stage (p = 0.004). The α1-globulin percentage composition was an independent prognostic factor for overall survival (hazard ratio 1.52, 95 % CI 1.04–2.23, p = 0.03). High percentage of α1-globulin in serum protein was also related to short recurrence survival (hazard ratio 1.56, 95 % CI 1.14–2.13, p = 0.005). Our results showed that the percentage of α1-globulin in serum protein may be an independent prognostic factor in NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer J Clin. 2013;63(1):11–30.

    Article  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  Google Scholar 

  3. Shio Y, Suzuki H, Kawaguchi T, Ohsugi J, Higuchi M, Fujiu K, et al. Carbohydrate status detecting by PNA is changeable through cancer prognosis from primary to metastatic nodal site: a possible prognostic factor in patient with node-positive lung adenocarcinoma. Lung Cancer. 2007;57(2):187–92. doi:10.1016/j.lungcan.2007.02.007.

    Article  PubMed  Google Scholar 

  4. Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999;17(5):1442–8.

    PubMed  CAS  Google Scholar 

  5. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129(1):87–93. doi:10.1016/j.jtcvs.2004.04.030.

    Article  PubMed  Google Scholar 

  6. Remiszewski P, Roszkowski-Sliz K, Wiatr E, Roszkowska-Sliz B, Zych J, Kurzyna M, et al. Prognosis in limited disease (LD) small cell lung cancer (SCLC) patients according to status performance, local extension of lesions, type of treatment and the completeness of staging. Pneumonol Alergol Pol. 2003;71(3–4):139–47.

    PubMed  Google Scholar 

  7. Sheng L, Luo M, Sun X, Lin N, Mao W, Su D. Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer. Int J Cancer. 2013;133(11):2720–5.

    PubMed  CAS  Google Scholar 

  8. Salmeron D, Chirlaque MD, Isabel Izarzugaza M, Sanchez MJ, Marcos-Gragera R, Ardanaz E, et al. Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 2012;106(9):1301–8. doi:10.1016/j.rmed.2012.06.006.

    Article  PubMed  CAS  Google Scholar 

  9. Rabinovitz M, Gavaler JS, Kelly RH, Prieto M, Van Thiel DH. Lack of increase in heterozygous alpha 1-antitrypsin deficiency phenotypes among patients with hepatocellular and bile duct carcinoma. Hepatology. 1992;15(3):407–10.

    Article  PubMed  CAS  Google Scholar 

  10. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood. 1995;85(3):765–71.

    PubMed  CAS  Google Scholar 

  11. Li Y, Krowka MJ, Qi Y, Katzmann JA, Song Y, Li Y, et al. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival. J Thorac Oncol. 2011;6(2):291–5. doi:10.1097/JTO.0b013e31820213fb.

    Article  PubMed  PubMed Central  Google Scholar 

  12. El-Akawi ZJ, Abu-Awad AM, Sharara AM, Khader Y. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients. Neuro Endocrinol Lett. 2010;31(1):113–6.

    PubMed  CAS  Google Scholar 

  13. O’Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician. 2005;71(1):105–12.

    PubMed  Google Scholar 

  14. Vavricka SR, Burri E, Beglinger C, Degen L, Manz M. Serum protein electrophoresis: an underused but very useful test. Digestion. 2009;79(4):203–10. doi:10.1159/000212077.

    Article  PubMed  CAS  Google Scholar 

  15. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.

    Article  PubMed  Google Scholar 

  16. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.

    Article  PubMed  Google Scholar 

  17. Van der Schouw YT, Verbeek AL, Ruijs JH. ROC curves for the initial assessment of new diagnostic tests. Fam Pract. 1992;9(4):506–11.

    Article  PubMed  Google Scholar 

  18. Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8(4):283–98.

    Article  PubMed  CAS  Google Scholar 

  19. Bata J, Colobert L, Biron A, Brune J. Study of various serum proteins in lung cancer. Immunoglobulins A, G, M, haptoglobin, alpha-1-antitrypsin, alpha-2-macroglobulin. Ann Biol Clin (Paris). 1977;35(4):297–303.

  20. Krecicki T, Leluk M. Acute phase reactant proteins—an aid to monitoring surgical treatment of laryngeal carcinoma. J Laryngol Otol. 1992;106(7):613–5.

    Article  PubMed  CAS  Google Scholar 

  21. Amiguet JA, Jimenez J, Monreal JI, Hernandez MJ, Lopez-Vivanco G, Vidan JR, et al. Serum proteolytic activities and antiproteases in human colorectal carcinoma. J Physiol Biochem. 1998;54(1):9–13.

    PubMed  CAS  Google Scholar 

  22. Coakley RJ, Taggart C, O’Neill S, McElvaney NG. Alpha1-antitrypsin deficiency: biological answers to clinical questions. Am J Med Sci. 2001;321(1):33–41.

    Article  PubMed  CAS  Google Scholar 

  23. Perlmutter DH. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest. 2002;110(11):1579–83. doi:10.1172/jci16787.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Luft FC. Alpha-1-antitrypsin and its relevance to human disease. J Mol Med (Berl). 1999;77(4):359–60.

    Article  PubMed  CAS  Google Scholar 

  25. Faust D, Raschke K, Hormann S, Milovic V, Stein J. Regulation of alpha1-proteinase inhibitor release by proinflammatory cytokines in human intestinal epithelial cells. Clin Exp Immunol. 2002;128(2):279–84.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Cichy J, Potempa J, Travis J. Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem. 1997;272(13):8250–5.

    Article  PubMed  CAS  Google Scholar 

  27. Ades EW, Hinson A, Chapuis-Cellier C, Arnaud P. Modulation of the immune response by plasma protease inhibitors. I. Alpha 2-macroglobulin and alpha 1-antitrypsin inhibit natural killing and antibody-dependent cell-mediated cytotoxicity. Scand J Immunol. 1982;15(1):109–13.

    Article  PubMed  CAS  Google Scholar 

  28. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. Br J Cancer. 1992;65(2):300–2.

  29. Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K, Koono M. Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am J Pathol. 1999;154(2):457–68.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumor spread in mice. Int Immunol. 1999;11(8):1247–52.

    Article  PubMed  CAS  Google Scholar 

  31. Muers MF, Shevlin P, Brown J. Prognosis in lung cancer: physicians’ opinions compared with outcome and a predictive model. Thorax. 1996;51(9):894–902.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  32. Kobayashi N, Usui S, Kikuchi S, Goto Y, Sakai M, Onizuka M, et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer. 2012;75(2):223–7. doi:10.1016/j.lungcan.2011.06.009.

    Article  PubMed  Google Scholar 

  33. Zhao W, Yang Z, Liu X, Tian Q, Lv Y, Liang Y, et al. Identification of alpha1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis. J Int Med Res. 2013;41(3):573–83. doi:10.1177/0300060513476582.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank all the patients and investigators involved in the study. The work was supported by Promotive research fund for young and middle-aged scientists of Shandong Province (BS2013YY066).

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021, People’s Republic of China

    Xiao Qu, Zhaofei Pang, Ying Wang, Kai Wang, Qi Liu & Jiajun Du

  2. Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021, People’s Republic of China

    Weiwei Yi

  3. Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021, People’s Republic of China

    Jiajun Du

Authors
  1. Xiao Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhaofei Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weiwei Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jiajun Du
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Qi Liu or Jiajun Du.

Additional information

Xiao Qu, Zhaofei Pang and Weiwei Yi have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qu, X., Pang, Z., Yi, W. et al. High percentage of α1-globulin in serum protein is associated with unfavorable prognosis in non-small cell lung cancer. Med Oncol 31, 238 (2014). https://doi.org/10.1007/s12032-014-0238-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0238-7

Keywords

Search

Navigation